Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2022.02.27.482147: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Infection assay was conducted by inoculating VeroE6/TMPRSS2 cells with each SARS-CoV-2 strain at an MOI of 0.003 for 1 h, followed by washing out free viruses and culturing cells with fresh medium.
    VeroE6/TMPRSS2
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of the study: This study was limited to cell culture infection assays, in which cell types and other conditions reflected drug sensitivities. However, viral targeting agents examined in this study (casirivimab, imdevimab, and S309 target Spike, EIDD-1931 target polymerase, and nirmatrelvir target main protease) were much less governed through cellular backgrounds, compared to host-targeting antivirals, and instead are more affected by viral factors such as sequence changes in the viral genome. Our assay at least compared the intrinsic antibody/drug sensitivity of SARS-CoV-2 variants side by side, helpful in discussing the impact of sequence substitutions on antibody/drug activities. Additionally, the analyses of animal and patient infections under treatment were further desired to understand drug efficacy. Yet, given the Omicron BA.2 wave’s urgency and the need for the scientific evidence to better combat this infectious disease, our data significantly present the potential diversity of drug/antibody efficacies among SARS-CoV-2 variants.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.